Thursday, May 2, 2024
ADVT 
International

Meghan: talk with Oprah without royals' input 'liberating'

Darpan News Desk The Canadian Press, 05 Mar, 2021 11:34 PM
  • Meghan: talk with Oprah without royals' input 'liberating'

Meghan, the Duchess of Sussex has described to Oprah Winfrey how “liberating” it was to have a conversation - let alone a sit-down interview - with the television host without royal minders.

“CBS This Morning” aired a clip on Friday of Winfrey speaking to Meghan about a conversation they had before the actor’s wedding to Prince Harry in May 2018.

The clip opens with Winfrey describing how she asked for an interview and Meghan recounting how there were others in the room and she wasn’t even supposed to be speaking with Winfrey.

“As an adult who lived a really independent life to then go into this construct that is um.. different than I think what people imagine it to be, it’s really liberating to be able to have the right and the privilege in some ways to be able to say yes,” Meghan tell Winfrey.

Winfrey’s interview with Meghan and Harry is set to air Sunday night in the United States on CBS and will air in Britain on Monday evening.

Despite stepping back from royal duties a year ago and moving to California, there still intense interest in the couple and their relationship with the royal family.

When Meghan was asked what was right about doing the interview now, she said it was because of the couple’s newfound freedom.

“That we’re on the other side of a lot of, a lot of life experience that’s happened,” Meghan said. And also that we have the ability to make our own choices in a way that I couldn’t have said yes to you then. That wasn’t my choice to make.”

MORE International ARTICLES

AstraZeneca resuming US testing of COVID-19 vaccine

AstraZeneca resuming US testing of COVID-19 vaccine
The AstraZenca vaccine, developed with Oxford University, is one of several coronavirus vaccine candidates in final-stage testing around the world.

AstraZeneca resuming US testing of COVID-19 vaccine

FDA approves first COVID-19 drug: antiviral remdesivir

FDA approves first COVID-19 drug: antiviral remdesivir
The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days — from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health.

FDA approves first COVID-19 drug: antiviral remdesivir

Here we go again: Trump, Biden reprise debate duel

Here we go again: Trump, Biden reprise debate duel
Instead, they're bracing for another show of vintage Trump, one in which he'll seek to be heard even in spite of his muted microphone.

Here we go again: Trump, Biden reprise debate duel

Getting ready for the gong show: Trump v. Biden II

Getting ready for the gong show: Trump v. Biden II
It's the sequel to last month's debate horror show between Donald Trump and Joe Biden, an invective-laced 90 minutes that laid bare the depths to which political discourse can sink in an American election year.

Getting ready for the gong show: Trump v. Biden II

US overdose deaths appear to rise amid coronavirus pandemic

US overdose deaths appear to rise amid coronavirus pandemic
Davidson lost his job. He started staying home alone in his apartment near Georgetown, Kentucky — depressed and yearning for his recovery support group that had stopped gathering in person, said his cousin Melanie Wyatt.

US overdose deaths appear to rise amid coronavirus pandemic

Pfizer: Mid-November earliest it can seek virus vaccine OK

Pfizer: Mid-November earliest it can seek virus vaccine OK
Another leading U.S. contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be Nov. 25.

Pfizer: Mid-November earliest it can seek virus vaccine OK